NYSEARCA:BBH
VanEck Vectors Biotech ETF News
$168.12
-0.480 (-0.285%)
At Close: May 21, 2024
Should You Invest in the VanEck Biotech ETF (BBH)?
07:32am, Tuesday, 22'nd Nov 2022
Sector ETF report for BBH
How Are Biotech ETFs Reacting to Q3 Earnings Releases?
09:02am, Wednesday, 09'th Nov 2022
Biotech earnings have come in upbeat in the third quarter.
Assessing the Strength of Biotech Dividends With BBH
10:08am, Friday, 21'st Oct 2022
Biotechnology usually isn't the first industry investors think of when it comes to dividends, but some of the more mature companies in the space do deliver payouts. Some of those names reside in the V
Should You Invest in the VanEck Biotech ETF (BBH)?
10:20am, Monday, 19'th Sep 2022 Zacks Investment Research
Sector ETF report for BBH
Should You Invest in the VanEck Biotech ETF (BBH)?
07:32am, Monday, 19'th Sep 2022
Sector ETF report for BBH
Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth
05:09pm, Thursday, 08'th Sep 2022
Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.
Consolidation Case for Biotech ETF BBH
02:24pm, Wednesday, 07'th Sep 2022
Eight months into 2022, it's fair to say that it's been a tepid year of deal-making in the biotechnology industry, and that's one reason why the related stocks and exchange traded funds are scuffling.
Why Now Could Be The Time To Consider Neuroscience Investments
04:45am, Saturday, 27'th Aug 2022
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic
What The Inflation Reduction Act Means For Drug Prices
01:24am, Friday, 26'th Aug 2022
The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
12:00pm, Thursday, 18'th Aug 2022 Zacks Investment Research
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
09:02am, Thursday, 18'th Aug 2022
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
Biotech Bounce-Back Could Be Durable
10:52am, Wednesday, 17'th Aug 2022
Following a lengthy wait that included plenty of downside and frustration, biotechnology stocks and exchange traded funds are finding a groove. For example, the VanEck Vectors Biotech ETF (BBH) is hig
3 Best Funds for Aggressive Investors
04:44pm, Thursday, 11'th Aug 2022
The best funds for aggressive investors is our topic for today. An aggressive investing strategy typically seeks returns that are greater than those offered by the broader stock market, such as the S&
Biotech Rebound Could Finally Be Afoot
08:29am, Tuesday, 09'th Aug 2022
A long-awaited biotechnology equity rebound could be materializing and some analysts believe it could have the momentum to carry into the end of 2022.
Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs
06:23pm, Wednesday, 03'rd Aug 2022
Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in i
